R&D
Clinical Study of EarlyTect¢ç Colon Cancer
In a pivotal clinical study, EarlyTect¢ç Colon Cancer Test has been proven to be able to diagnose colorectal cancer with 90.2% sensitivity and 90.2% specificity, and 89.1% sensitivity for early stages (0-II) on 585 subjects at Severance Hospital and Health Promotion Center of Severance Hospital. In addition, the sensitivity is not associated with sex, age, tumor stage and tumor location. EarlyTect¢ç Colon CancerSensitivity
90.2%Specificity
90.2%Sensitivity of EarlyTect¢ç CRC Test to clinical stages
Stage 0
100%
(n=3/3)Stage¥°
85.5%
(n=47/55)Stage¥±
91.4%
(n=64/70)Stage¥²
89.6%
(n=86/96)Stage ¥³
100%
(n=21/21)In a pilot clinical study, EarlyTect¢ç Bladder Cancer Test has been shown to be able to diagnose bladder cancer with 84.0% sensitivity and 94.0% specificity,
and 74.0% sensitivity for pTa, early stages of bladder cancer, on 574 hematuria subjects at Chungnam National University Hospital, Konyang University Hospital and Daejeon Catholic St. Mary's Hospital.
In a pivotal clinical study, EarlyTect¢ç Lung Cancer Test has been proven to be able to diagnose lung cancer with 77.8% sensitivity and 92.3% specificity, and 62.2% sensitivity for early stages (I-II) on 522 subjects at Kyungpook National University Chilgok Hospital. In addition, the sensitivity is not associated with tumor stage, smoking history, or age.